Trial · NCT05426044
Metformin as a Neuroprotective Therapy for Glaucoma
NCT05426044, Phase 2, Recruiting, Christopher Kai Shun Leung
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin as a Neuroprotective Therapy for Glaucoma. Trials, record NCT05426044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05426044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin as a Neuroprotective Therapy for Glaucoma
- NCT number
- NCT05426044
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 125 participants, estimated
- Lead sponsor
- Christopher Kai Shun Leung
- Conditions
- Glaucoma
- Interventions
- Metformin, Placebo
- First posted
- 2022-06-21
- Last updated
- 2025-11-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rates of RNFL/GCIPL thinning (Evaluation of Neuroprotection) | 24 months | For evaluation of neuroprotection, the rates of RNFL thinning between the metformin-treated group and the placebo-treated group will be compared using a linear mixed model after adjusting for clustering between fellow eyes and covariates (i.e. signal strength, baseline RNFL thickness, IOP during follow-up, age, and axial length) will be exported for the analysis. |
| Primary | Change in visual field sensitivity (Evaluation of Neuroenhancement) | 4 weeks | For evaluation of neuroenhancement, the change in VF sensitivity between baseline and one month will be determined from each treatment group using linear mixed modeling, after adjusting for clustering between fellow eyes and covariates. Only eyes with progressive RNFL/GCIPL thinning by TPA or GPA at the baseline will be included in the analysis. |
| Secondary | Rates of change of VF MD and VFI | 24 months | The rates of change of VF MD and VFI will be compared between treatment groups with linear mixed models as described; differences in time from baseline to the event of progressive RNFL/GCIPL thinning (by TPA or GPA) and VF progression (by EMGT criteria) between treatment groups will be compared with Cox proportional hazards models using shared-frailty to adjust for correlation between fellow eyes. Missing data (e.g. lost to follow-up) will be imputed using multiple imputation by chained equations. |
| Other | Risk factors associated with the rates of RNFL thinning and VF MD/VFI decline | 24 months | Risk factors (i.e. age, axial length, corneal hysteresis, CCT, RNFL thickness, and VF MD at the baseline visit, and IOP during follow-up) associated with (A) the rate of progressive RNFL thinning and (B) the rate of VF MD decline will be identified with linear mixed models. Time (i.e. follow-up duration), covariates (i.e. the risk factors), and the interactions between time and covariates will be included in the models as fixed effects with random intercepts and random slopes accommodating different baseline values and different rates of change of RNFL thickness and VF MD for individual eyes. IOP measurements over the 2-year follow-up will be compared between treatment groups with linear mixed models after adjusting for clustering between fellow eyes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05426044
GET https://conductscience.org/api/trials/v1/NCT05426044/registered